Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference
Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference
The presentation will be broadcast live and archived on the Company's website at in the Investors section.– Marks first time as a public company that Conavi is presenting at an investor event –
这是Conavi作为一家上市公司第一次在投资者活动中进行展示
– Live webcast presentation on Wednesday, December 11th at 3:35 p.m. ET –
– 网络直播演示将于12月11日星期三下午3:35（东部时间）进行 –
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) ("Conavi Medical" or the "Company"), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Chief Executive Officer, Thomas Looby, will present an update on the Company's business at the MedInvest MedTech, AI & Digital Health Conference on Wednesday, December 11, 2024 at 3:35 p.m. Eastern Time in New York City.
多伦多，2024年12月10日（全球新闻网）—— Conavi医疗CORP（TSXV: CNVI）（"Conavi医疗"或"公司"），是一家专注于设计、制造和营销影像技术以指导常见的微创心血管手术的商业阶段公司，今天宣布首席执行官托马斯·卢比（Thomas Looby）将在2024年12月11日东部时间下午3:35在纽约市的MedInvest MedTech，人工智能与互联网医疗大会上介绍公司的业务更新。
The presentation will be broadcast live and archived on the Company's website at in the Investors section.
该演示将进行现场直播并在公司网站的投资者部分归档。
About Conavi Medical
关于康纳维医疗
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit .
Conavi Medical专注于设计、制造和营销成像技术，以指导常见的微创心血管手术。其专利的Novasight混合系统是第一个结合了血管内超声(IVUS)和光学相干断层扫描(OCT)的系统，能够同时和共配准成像冠状动脉。Novasight混合系统已获得美国食品和药物管理局的510(k)许可；并获得加拿大卫生部、中国国家药品监督管理局和日本厚生劳动省的临床使用监管批准。更多信息，请访问。
Cautionary Statement Regarding Forward-Looking Information
关于前瞻性信息的警示声明
This news release contains "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi's future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi's plans for the commercialization of its Novasight Hybrid System.
本新闻稿包含适用的加拿大和美国证券法意义上的“前瞻性声明”，反映了Conavi管理层对未来增长、运营成果、表现和业务前景及机会的当前期望。前瞻性声明通常但并不总是通过“可能”、“将”、“可以”、“会”、“预计”、“相信”、“计划”、“期待”、“打算”、“估计”、“潜在的”和类似表达来识别，尽管这些词可能并不出现在所有的前瞻性声明中。本声明中出现的前瞻性声明可能包括但不限于对Conavi实施其Novasight混合系统商业化计划的参考。
These forward-looking statements reflect management's current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi's ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the "Risk Factors" sections of the joint information circular of Conavi dated August 30, 2024 (which may be viewed at ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
These forward-looking statements reflect management's current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi's ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the "Risk Factors" sections of the joint information circular of Conavi dated August 30, 2024 (which may be viewed at ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
无论是TSX创业公司交易所还是其监管服务提供者（按TSX创业公司交易所政策中的定义）均不对本新闻稿的充足性或准确性承担责任。
Contacts
联系人
Stephen Kilmer
Investor Relations
(647) 872-4849
stephen.kilmer@conavi.com
斯蒂芬·基尔默
投资者关系
(647) 872-4849
stephen.kilmer@conavi.com
Stefano Picone
Chief Financial Officer
(416) 483-0100
斯特凡诺·皮科内
首席财务官
(416) 483-0100
